Stage I/II Nasal NK Cell Lymphoma

计划入组 1 人 · 首次发布于 2011 年 3 月 23 日

Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

计划入组 83 人 · 首次发布于 2016 年 11 月 28 日

Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell Lymphoma

计划入组 30 人 · 首次发布于 2023 年 6 月 12 日

CAR-NK-019

anti-CD19 CAR-T/CAR-NK cells (B-cell lymphoma/acute B-lymphoblastic leukemia)

NK cell

AUSTRALASIAN LEUKAEMIA & LYMPHOMA GROUP

Australia

Gamida Cell

Israel

GAMIDA CELL INC.

United States

Antengene to Present Selinexor Data in Relapsed/Refractory Multiple Myeloma and Extranodal NK/T-Cell Lymphoma at ASH 2024

Kymera's KT-333 Demonstrates Antitumor Activity in Hematological Cancers in Phase 1 Trial

Antengene's Selinexor Shows Promise in Multiple Myeloma and Lymphoma Studies